Early Evidence that Larotrectinib Is Safe and Effective in Adults with Solid Tumors Characterized by TRK Fusions

Results from a phase 1 study suggest that larotrectinib could be a new standard of care in TRK-fusion cancers.

from Latest articles from Cancer Therapy Advisor News http://bit.ly/2TiNlsx